Practical application of recombinant thyrotropin testing in clinical practice.

Area of Science:

• Endocrinology
• Oncology
• Diagnostic Medicine

Background:

• Thyroid cancer management requires regular monitoring for recurrence.
• Traditional monitoring involves thyroid hormone withdrawal, leading to hypothyroidism.
• Recombinant thyrotropin (rTSH) offers a potential alternative for diagnostic testing.

Purpose of the Study:

• To review indications for recombinant thyrotropin (rTSH) use.
• To outline the implementation of rTSH diagnostic testing in treated thyroid cancer patients.
• To compare rTSH-stimulated testing with conventional thyroid hormone withdrawal.

Main Methods:

• Review of published clinical trials comparing rTSH-stimulated testing and hormone withdrawal.
• Description of appropriate candidates for rTSH testing.
• Presentation of typical rTSH testing and follow-up schedules.
• Overview of coding and documentation for reimbursement.

Main Results:

• rTSH-stimulated testing shows comparable sensitivity to hormone withdrawal for detecting recurrent thyroid cancer using (131)I scans and thyroglobulin measurements.
• Patients undergoing rTSH testing experience fewer symptoms and improved mood compared to hormone withdrawal.
• Recommended testing schedules vary based on patient risk stratification (low vs. moderate-to-high).
• rTSH testing is increasingly covered by major insurance providers.

Conclusions:

• Radioiodine scanning and thyroglobulin measurement after rTSH injection are effective monitoring options for treated thyroid cancer.
• rTSH testing avoids the adverse effects of hypothyroidism associated with hormone withdrawal.
• This approach provides a valuable alternative for patient management and follow-up.